NCT06914869View on ClinicalTrials.gov

Drug-Drug Interaction Potential of Mavorixafor

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

May 19, 2025

Study Completion Date

May 19, 2025

Conditions
Healthy Participants
Interventions
DRUG

Mavorixafor

Mavorixafor will be administered per schedule specified in the arm description.

DRUG

Carbamazepine

Carbamazepine will be administered per schedule specified in the arm description.

DRUG

Efavirenz

Efavirenz will be administered per schedule specified in the arm description.

Trial Locations (1)

21225

Parexel International LLC, Baltimore

Sponsors

Lead Sponsor

X4 Pharmaceuticals
All Listed Sponsors
lead

X4 Pharmaceuticals

INDUSTRY